Michael J. Farrell - Sep 15, 2023 Form 4 Insider Report for RESMED INC (RMD)

Signature
Michael J. Farrell, Chief Executive Officer
Stock symbol
RMD
Transactions as of
Sep 15, 2023
Transactions value $
-$502,726
Form type
4
Date filed
9/19/2023, 02:54 PM
Previous filing
Aug 18, 2023
Next filing
Oct 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $328K +5.68K +1.26% $57.76 455K Sep 15, 2023 Direct F1
transaction RMD ResMed Common Stock Sale -$831K -5.68K -1.25% $146.35 449K Sep 15, 2023 Direct F1, F2
holding RMD ResMed Common Stock 4.09K Sep 15, 2023 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -5.68K -27.7% $0.00 14.8K Sep 15, 2023 ResMed Common Stock 5.68K $57.76 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $145.09 to 148.07. The price reported above reflects the weighted average sale price.
F3 Options are exercisable 1/3 each year beginning 1 year from date of grant.